Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 7/2001

01-07-2001 | Review Article

Therapeutic Advances in Biological Response Modifiers in the Treatment of Cutaneous T-Cell Lymphoma

Authors: Dr Carmela C. Vittorio, Alain H. Rook, Lars E. French, Michael Shapiro, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins

Published in: BioDrugs | Issue 7/2001

Login to get access

Abstract

Cutaneous T-cell lymphoma (CTCL) is most often a skin-infiltrating malignancy of clonal CD4+ T-cells. Therapy is based on staging and the likelihood of progression. Biological response modifiers and chemotherapeutic agents are used to preserve the integrity of the host antitumour response while selectively targeting the malignant cells. The biological response-modifying treatment options currently used to treat CTCL are bexarotene, denileukin diftitox, interferon-α, interferon-γ and interleukin-12, as well as extracorporeal photopheresis and phototherapy. A combination therapy approach maximises response in patients with advanced CTCL. Biological response modifiers in combination with photopheresis are used for patients with the leukaemic phase of the disease. Among the majority of patients with advanced stage disease so treated, immune response augmentation appears to prolong survival. Future areas of research should assess not only survival and optimal treatment combinations, but also quality of life during the treatment period.
Literature
1.
Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996; 88: 2385–409PubMed
2.
Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26–32CrossRefPubMed
3.
Vowels BR, Cassin M, Vonderheid E, et al. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90–4CrossRefPubMed
4.
Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132: 1309–13CrossRefPubMed
5.
Vonderheid EC, Tan ET, Kantor AF, et al. Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416–28CrossRefPubMed
6.
Kaye FJ, Bunn Jr PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784–90CrossRefPubMed
7.
Rook AH, Lessin SR, Jaworsky C, et al. Immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T-cells. Arch Dermatol 1993; 129: 486–9CrossRefPubMed
8.
Rook AH, Kubin M, Cassin M, et al. Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995; 154: 1491–8PubMed
9.
Peleman R, Wu J, Rargeas C, et al. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 1989; 170; 1751–6CrossRefPubMed
10.
D’Andrea A, Aste-Amea M, Valiante NM, et al. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–8CrossRefPubMed
11.
Boehm MF, Heyman RA, Nagpal S. A new generation of retinoid drugs for the treatment of dermatological disease. Emerg Drugs 1997; 2: 287–303CrossRef
12.
13.
Sherman S, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340: 1075–9CrossRefPubMed
14.
Package insert, Targretin Gel, 1%. Ligand Pharmaceuticals
15.
Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997; 33: S34–6CrossRefPubMed
16.
Duvic M, Cather JC, Maize J, et al. DAB389IL-2 diphtheria fusion toxin reduces clinical responses in tumor stage cutaneous T-cell lymphoma. Am J Hematol 1998; 58: 78–90CrossRef
17.
Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Clin North Am 1995; 9: 1089–107
18.
Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alpha 2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395–407CrossRefPubMed
19.
Rook AH, Yoo EK, Grossman DJ, et al. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 1998; 10: 170–4CrossRefPubMed
20.
Knobler RM, Radaszkiewicz T. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa 2b and retinoids. J Am Acad Dermatol 1991; 24: 247–52CrossRefPubMed
21.
Dreno B, Celorier P, Litroux P. Roferon-A in combination with Tegason in cutaneous T-cell lymphomas. Acta Haematol 1993; 89 Suppl. 1: 28–32CrossRef
22.
Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 203–7CrossRefPubMed
23.
Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and with recombinant interferon alfa. J Am Acad Dermatol 1996; 35: 946–57CrossRefPubMed
24.
Fox FE, Niu Z, Lessin S, et al. Cytokine regulation of the growth of clonal malignant T-cells from patients with Sézary syndrome [abstract]. J Invest Dermatol 1997; 108: 552CrossRef
25.
Gottlieb SL, Fox FE, Cassin M, et al. Interleukin 5 expression by peripheral blood mononuclear cells in Sézary syndrome correlates with peripheral eosinophilia and is suppressed by interferon alfa [abstract]. J Invest Dermatol 1995; 104: 683
26.
Platsoucas CD, Fox FE, Oleszak E, et al. Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Res 1989; 9: 849–58
27.
Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferony for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208–12CrossRefPubMed
28.
Fox FE, Kubin M, Cassin M, et al. Retinoids synergize with interleukin-12 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1999; 19: 407–15CrossRefPubMed
29.
Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 Therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902–8PubMed
30.
Rook AH, Foss F, Wood G, et al. A phase 2 open-label study reveals that recombinant human interleukin-12 (rhIL-12) is efficacious in patients with early stage cutaneous T-cell lymphoma (CTCL) [abstract]. J Invest Dermatol 2000; 114: 880
31.
Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction by ultraviolet A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235–42CrossRefPubMed
32.
Rook AH, Suchin KR, Kao DMF, et al. Photopheresis: clinical applications and mechanisms of action. J Invest Dermatol Symp Proc 1999; 4: 85–9CrossRef
33.
Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracoporeal photopheresis in the management of patients with erythrodemic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43: 54–60CrossRefPubMed
34.
Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257–63PubMed
35.
Ramsey DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1031–56
36.
Clark C, Dawe RS, Evans AT, et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748–52CrossRefPubMed
37.
Suchin KR, DeNardo B, Macey W, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 15-year experience at a single institution. Pacific Dermatologic Association; 2000 Sep 13–17; Victoria, BC
Metadata
Title
Therapeutic Advances in Biological Response Modifiers in the Treatment of Cutaneous T-Cell Lymphoma
Authors
Dr Carmela C. Vittorio
Alain H. Rook
Lars E. French
Michael Shapiro
Michael S. Lehrer
Jacqueline M. Junkins-Hopkins
Publication date
01-07-2001
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 7/2001
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200115070-00002

Other articles of this Issue 7/2001

BioDrugs 7/2001 Go to the issue

Review Article

Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child

Review Article

Molecular Biology of Pancreatic Cancer

Leading Article

Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C

Adis Drug Evaluation

Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders